Skip to main content
. 2018 Sep 26;14:1789–1797. doi: 10.2147/TCRM.S176214

Figure 2.

Figure 2

The pooled absolute rate of pCR for the concurrent (A) and nonconcurrent (B) use of trastuzumab and anthracycline-based NAC for HER2-positive breast cancer.

Abbreviations: HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response.